Newscast – Page 91 – media

Where AI has the most promise for reducing healthcare costs

AI technology is already in use in certain aspects of healthcare, such as diagnostic imaging, but it’s being underutilized in several others.
- Source: HealthcareITNews
- 724
- April 10, 2018
AI digital health EHR Market Views
Novo moves into sickle cell with $400M EpiDestiny deal

Novo Nordisk has moved into sickle cell disease through a licensing deal (PDF) with EpiDestiny. The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.
- Source: Fiercebiotech
- 707
- April 9, 2018
epigenetic Market Views sickle cell disease
Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.

Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.
- Source: Businesswire;
- 597
- April 9, 2018
acquisition CDI Market Views non-antibiotic
This DARPA-Developed Brain Implant Can Help Recover Your Memories

No longer science fiction, a "prosthetic memory" neural implant can actually improve short term memories.
- Source: Popular Mechanics
- 720
- April 9, 2018
brain medical device Researches
Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe

Biogen expects to launch IMRALDI in Europe on October 16, 2018 Biogen will be the first company to offer biosimilars of all three major anti-TNF therapies in Europe
- Source: businesswire
- 628
- April 9, 2018
AbbVie Biogen biosimilar Samsung Bioepis
HEALTHY PETS RAISES $500,000 FOR VETERINARY TELEMEDICINE SERVICE

Toronto-based Healthy Pets has launched with $500,000 in seed funding from Arlene Dickinson’s District Ventures Capital.
- Source: Betakit
- 661
- April 9, 2018
Company Insights digital health Telemedicine
Rejection–FDA Issues CLRs for Two Celltrion and Teva Biosimilars

The U.S. Food and Drug Administration (FDA) issued two Complete Response Letters (CRLs) to South Korean manufacturer Celltrion. One was for a proposed biosimilar for Genentech and Biogen’s Rituxan for lymphomas and leukemias, and a proposed biosimilar to AbbVie’s Humira for rheumatoid arthritis, plaque psoriasis, Crohn’s disease and other autoimmune disorders.
- Source: biospace
- 642
- April 9, 2018
AbbVie biosimilar FDA Genentech
Pfizer announces second year of UK-based startup innovation competition

Pfizer announced today that it is receiving applications for its Pfizer Healthcare Hub: London competitive grant. This is the second time that Pfizer has held the startup-focused program, which representatives from biopharmaceutical company said had a strong inaugural year in 2017.
- Source: MobiHealthNews
- 681
- April 9, 2018
Company Insights healthcare Pfizer
Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio

Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
- Source: finance.yahoo
- 515
- April 8, 2018
CAR-T therapy immuno-oncology Market Views
Hydrogel delivery enables long-lasting, ‘flare-responsive’ arthritis treatment

Although inflammatory arthritis can be treated systemically, drugs are often injected directly into affected areas, particularly when the disease affects just one or a few joints. Problem is, injectable drugs are usually cleared quickly from the joint, limiting their effectiveness. A new delivery system could improve the efficacy and durability of arthritis treatments, as well as cut down on nasty side effects caused by systemic therapy.
- Source: fiercebiotech
- 492
- April 8, 2018
arthritis Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.